Breaking News Instant updates and real-time market news.

CNAT

Conatus

$7.58

0.42 (5.87%)

, NVS

Novartis

$73.62

0.88 (1.21%)

08:09
04/21/17
04/21
08:09
04/21/17
08:09

Conatus price target raised to $12 from $4 at Roth Capital

Roth Capital analyst Sa'ar Yaniv raised his price target for Conatus (CNAT) to $12 from $4 following discussions with management, 2016 results, assessment of the competitive cirrhosis space, and clarity from the Novartis (NVS) deal. The analyst believes Conatus' shares are undervalued and reiterates a Buy rating on the stock.

CNAT

Conatus

$7.58

0.42 (5.87%)

NVS

Novartis

$73.62

0.88 (1.21%)

  • 03

    May

  • 06

    Jun

  • 26

    Jun

CNAT Conatus
$7.58

0.42 (5.87%)

09/20/16
STFL
09/20/16
NO CHANGE
Target $6
STFL
Buy
Stifel says Conatus emricasan an interesting asset amid increased focus on NASH
Following Allergan's (AGN) acquisition of small-cap NASH play Tobira (TBRA), Stifel analyst Stephen Willey notes there are some "interesting" similarities between Conatus (CNAT) and the latter. However, the analyst points out that the clearest distinctions between the two are Conatus' emphasis on some of the downstream consequences of NASH fibrosis and the amount of meaningful clinical data generated to date. Willey still thinks Conatus' emricasan is an interesting asset, but urges investors seeking Tobira-like premiums to exercise a level of caution. He reiterates a Buy rating and $6 price target on Conatus' shares. In afternoon trading, shares of Conatus have gained about 20% to $2.10.
12/20/16
HCWC
12/20/16
NO CHANGE
Target $18
HCWC
Buy
Conatus price target doubled to $18 after Novartis pact at H.C. Wainwright
H.C. Wainwright analyst Ed Arce called Conatus' (CNAT) license and collaboration agreement with Novartis (NVS) a "transformational" deal that he believes ends any uncertainty about whether sufficient financial resources exist to support emricasan's full development. The analyst, who is positive on the deal both strategically and financially and predicted shares Conatus will trade up "at least 100% today," raised his price target on the stock to $18 from $9 and affirmed his Buy rating.
12/20/16
STFL
12/20/16
NO CHANGE
STFL
Conatus price target raised to $7 from $5 at Stifel
Stifel analyst Stephen Willey says that Novartis' (NVS) decision to collaborate with Conatus (CNAT) on its emricasan treatment marks a positive turning point for Conatus. Willey notes that the deal provides Conatus with funding and the opportunity to "pursue combination development with Novartis' FXR agonist LJN452," which he believes has synergies with emricasan. The analyst keeps a Buy rating on Conatus.
12/20/16
RHCO
12/20/16
NO CHANGE
RHCO
Conatus price target raised to $26 from $17 at SunTrust
After Conatus (CNAT) announced a partnership deal with Novartis (NVS), SunTrust analyst John Boris says the deal is "transformational" for Conatus. The analyst thinks that the deal will be worth about $1B to Conatus. He believes that the deal makes strategic sense to Conatus because of the potential synergies in the mechanism of action between its NASH treatment and that of Novartis (NVS). Boris keeps a Buy rating on Conatus.
NVS Novartis
$73.62

0.88 (1.21%)

03/14/17
LEER
03/14/17
NO CHANGE
LEER
Monitoring requests put Novartis Kisqali at marketing disadvantage, says Leerink
Leerink analyst Seamus Fernandez notes that Novartis (NVS) announced the FDA approval of its CDK4/6 inhibitor Kisqali in combination with an aromatase inhibitor for the first-line treatment of post-menopausal women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. The analyst says that the label contains warnings for QT prolongation as well as liver toxicity, both of which necessitate frequent monitoring. Although Kisqali appears to have similar efficacy to Pfizer (PFE) approved Ibrance, the latter's label does not include these warnings or monitoring requirements, he points out, adding that he continues to see Ibrance maintaining long-term market dominance in the CDK4/6 class.
04/05/17
COWN
04/05/17
DOWNGRADE
Target $77
COWN
Market Perform
Novartis downgraded to Market Perform from Outperform at Cowen
Cowen analyst Steve Scala downgraded Novartis to Market Perform and lowered his price target for the shares to $77 from $87. The analyst believes the company's earnings growth looks below the industry average given the current weakness in Alcon and Entresto's slow rollout.
04/05/17
04/05/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AstraZeneca (AZN) downgraded to Neutral from Buy at UBS. 2. Novartis (NVS) downgraded to Market Perform from Outperform at Cowen with analyst Steve Scala saying he believes the company's earnings growth looks below the industry average given the current weakness in Alcon and Entresto's slow rollout. 3. MSG Networks (MSGN) downgraded to Neutral following NY Post report at Macquarie with analyst Tim Nollen citing valuation and maintained its $26 price target. 4. Generac (GNRC) downgraded to Sector Weight from Overweight at KeyBanc with analyst Jeffrey Hammond citing concerns that increased pricing incentives and normalizing storm activity are impacting the growth for the company's Residential home standby business. 5. Amgen (AMGN) downgraded to Hold from Buy at Jefferies with analyst Eun Yang saying she believes upside in the stock will likely be "muted" after her payor poll indicated continuing reimbursement challenges for Repatha, Amgen's PCSK9 inhibitor to treat high cholesterol. Yang also sees a "scarcity of blockbuster potential pipeline products" and feels a transformative acquisition is unlikely. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/18/17
WELS
04/18/17
NO CHANGE
WELS
Allergan partnership a 'promising free option,' says Wells Fargo
Wells Fargo analyst David Maris views Allergan's (AGN) partnership with Novartis (NVS) to conduct a Phase IIb study using its cenicriviroc and Novartis's lead FXR agonist for the treatment of nonalcoholic steatohepatitis as a "promising free option." The deal is a way to maximize Allergan's shots-on-goal in combination NASH treatments, Maris tells investors in a research note. He has an Outperform rating on Allergan shares.

TODAY'S FREE FLY STORIES

VCEL

Vericel

$6.55

0.3 (4.80%)

12:46
01/18/18
01/18
12:46
01/18/18
12:46
Hot Stocks
RTW Invesmtents reports 5.04% passive stake in Vericel »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

DDAIF

Daimler AG

$90.67

0.17 (0.19%)

12:45
01/18/18
01/18
12:45
01/18/18
12:45
Periodicals
Daimler, Bosch suffer walkouts in industrial labor dispute, Reuters says »

Approximately 44,000…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOLD

Amicus

$15.78

0.71 (4.71%)

12:45
01/18/18
01/18
12:45
01/18/18
12:45
Options
Amicus call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$113.44

0.45 (0.40%)

12:41
01/18/18
01/18
12:41
01/18/18
12:41
Periodicals
JPMorgan sued for over $875M by Nigeria over 2011 oilfield deal, Reuters reports »

JPMorgan has been sued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

FSNN

Fusion Telecommunications

$3.83

-0.03 (-0.78%)

12:33
01/18/18
01/18
12:33
01/18/18
12:33
Hot Stocks
Cooper Creek Partners reports 5.17% passive stake in Fusion Telecommunications »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,295.00

-9.86 (-0.76%)

, MS

Morgan Stanley

$55.59

0.235 (0.42%)

12:29
01/18/18
01/18
12:29
01/18/18
12:29
General news
On The Fly: Top stock stories at midday »

Stock futures were above…

AMZN

Amazon.com

$1,295.00

-9.86 (-0.76%)

MS

Morgan Stanley

$55.59

0.235 (0.42%)

LGF.A

Lionsgate

$34.99

2.71 (8.40%)

CBS

CBS

$61.09

2.19 (3.72%)

VIAB

Viacom

$31.96

0.58 (1.85%)

VIA

Viacom

$37.85

0.95 (2.57%)

GNC

GNC Holdings

$4.95

1.48 (42.65%)

PTC

PTC

$66.70

1.41 (2.16%)

AA

Alcoa

$52.37

-4.6199 (-8.11%)

ENDP

Endo

$7.69

-0.32 (-4.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 18

    Jan

  • 19

    Jan

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 15

    Feb

  • 18

    Mar

IP

International Paper

$62.23

0.74 (1.20%)

12:25
01/18/18
01/18
12:25
01/18/18
12:25
Options
International Paper call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

FMC

FMC Corporation

$88.41

-5.45 (-5.81%)

12:23
01/18/18
01/18
12:23
01/18/18
12:23
Recommendations
FMC Corporation analyst commentary  »

FMC Corporation pullback…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

  • 07

    Mar

BBBY

Bed Bath & Beyond

$23.40

0.39 (1.69%)

12:21
01/18/18
01/18
12:21
01/18/18
12:21
Hot Stocks
Bed Bath & Beyond recalls Hudson Comforters on mold exposure 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

COLB

Columbia Banking

$45.94

0.36 (0.79%)

12:19
01/18/18
01/18
12:19
01/18/18
12:19
Hot Stocks
Columbia Bank names Lisa Dow chief risk officer »

Columbia Bank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

ACOR

Acorda Therapeutics

$24.75

-0.3 (-1.20%)

12:17
01/18/18
01/18
12:17
01/18/18
12:17
Periodicals
Acorda Therapeutics jumps after web report about takeover approach »

According to a report…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

12:17
01/18/18
01/18
12:17
01/18/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
01/18/18
01/18
12:16
01/18/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:15
01/18/18
01/18
12:15
01/18/18
12:15
General news
Atlanta Fed's Q4 GDPNow estimate was raised to 3.4%: »

Atlanta Fed's Q4…

AMZN

Amazon.com

$1,295.00

-9.86 (-0.76%)

, SNE

Sony

$49.18

-0.6438 (-1.29%)

12:12
01/18/18
01/18
12:12
01/18/18
12:12
Periodicals
Amazon looks to compete in commercial films, less indies, Reuters says »

Amazon (AMZN) is looking…

AMZN

Amazon.com

$1,295.00

-9.86 (-0.76%)

SNE

Sony

$49.18

-0.6438 (-1.29%)

FOX

21st Century Fox

$36.49

0.7 (1.96%)

TWX

Time Warner

$92.31

0.14 (0.15%)

VIA

Viacom

$37.85

0.95 (2.57%)

CMCSA

Comcast

$41.68

-0.14 (-0.33%)

DIS

Disney

$111.33

-0.64 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 19

    Jan

  • 24

    Jan

  • 06

    Feb

  • 07

    Feb

  • 08

    Feb

  • 18

    Mar

MELI

MercadoLibre

$340.45

0.6 (0.18%)

12:10
01/18/18
01/18
12:10
01/18/18
12:10
Options
$45.5M option print in MercadoLibre »

$45.5M option print in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMC

FMC Corporation

$87.26

-6.6001 (-7.03%)

, SQM

SQM

$57.76

-1.79 (-3.01%)

12:06
01/18/18
01/18
12:06
01/18/18
12:06
Recommendations
FMC Corporation, SQM analyst commentary  »

FMC Corporation selloff…

FMC

FMC Corporation

$87.26

-6.6001 (-7.03%)

SQM

SQM

$57.76

-1.79 (-3.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

  • 07

    Mar

AXP

American Express

$100.20

-0.56 (-0.56%)

, V

Visa

$122.37

0.39 (0.32%)

12:06
01/18/18
01/18
12:06
01/18/18
12:06
Earnings
On The Fly: What to watch in credit card space earnings reports »

American Express (AXP) is…

AXP

American Express

$100.20

-0.56 (-0.56%)

V

Visa

$122.37

0.39 (0.32%)

MA

MasterCard

$164.92

0.6 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 01

    Feb

  • 01

    Feb

DIS

Disney

$111.22

-0.75 (-0.67%)

12:03
01/18/18
01/18
12:03
01/18/18
12:03
Hot Stocks
Disney, Twitch announce multi-year content partnership »

Social video service…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 06

    Feb

INTC

Intel

$44.39

1.25 (2.90%)

12:01
01/18/18
01/18
12:01
01/18/18
12:01
Hot Stocks
Intel debuts technologies, including RealSense Volumetric Content Capture »

During the 2018 Sundance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

FMC

FMC Corporation

$87.26

-6.6 (-7.03%)

, SQM

SQM

$57.49

-2.065 (-3.47%)

12:00
01/18/18
01/18
12:00
01/18/18
12:00
Recommendations
FMC Corporation, SQM analyst commentary  »

FMC Corporation pullback…

FMC

FMC Corporation

$87.26

-6.6 (-7.03%)

SQM

SQM

$57.49

-2.065 (-3.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

  • 07

    Mar

SBAC

SBA Communications

$161.47

1.62 (1.01%)

12:00
01/18/18
01/18
12:00
01/18/18
12:00
Options
One-day put sellers in SBA Comm »

One-day put sellers in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGF.A

Lionsgate

$33.90

1.62 (5.02%)

, CBS

CBS

$61.09

2.19 (3.72%)

11:58
01/18/18
01/18
11:58
01/18/18
11:58
Hot Stocks
Lionsgate jumps after report on potential takeover interest »

Shares of Lionsgate…

LGF.A

Lionsgate

$33.90

1.62 (5.02%)

CBS

CBS

$61.09

2.19 (3.72%)

VIAB

Viacom

$31.96

0.58 (1.85%)

VIA

Viacom

$37.85

0.95 (2.57%)

AMZN

Amazon.com

$1,295.00

-9.86 (-0.76%)

VZ

Verizon

$52.78

1.055 (2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 18

    Jan

  • 19

    Jan

  • 23

    Jan

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

  • 15

    Feb

  • 18

    Mar

ADP

ADP

$122.05

2.66 (2.23%)

, CSOD

Cornerstone OnDemand

$39.28

0.34 (0.87%)

11:52
01/18/18
01/18
11:52
01/18/18
11:52
Conference/Events
Stephens enterprise software analyst holds analyst/industry conference call »

Enterprise Software…

ADP

ADP

$122.05

2.66 (2.23%)

CSOD

Cornerstone OnDemand

$39.28

0.34 (0.87%)

MSFT

Microsoft

$90.14

1.79 (2.03%)

ORCL

Oracle

$50.26

-0.01 (-0.02%)

PAYC

Paycom

$88.34

-0.01 (-0.01%)

PCTY

Paylocity

$49.46

0.71 (1.46%)

SAP

SAP

$111.45

0.2601 (0.23%)

ULTI

Ultimate Software

$226.26

3.48 (1.56%)

WDAY

Workday

$112.26

2.17 (1.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 22

    Jan

  • 26

    Jan

  • 31

    Jan

  • 31

    Jan

  • 06

    Feb

  • 06

    Feb

  • 07

    Feb

  • 13

    Feb

  • 26

    Feb

  • 13

    Mar

  • 14

    Mar

DXCM

Dexcom

$56.32

-0.09 (-0.16%)

, ABT

Abbott

$58.77

-0.22 (-0.37%)

11:51
01/18/18
01/18
11:51
01/18/18
11:51
Hot Stocks
Dexcom dips with Cigna deeming Abbott's Libre medically necessary »

Shares of Dexcom (DXCM)…Reference Link

DXCM

Dexcom

$56.32

-0.09 (-0.16%)

ABT

Abbott

$58.77

-0.22 (-0.37%)

CI

Cigna

$218.45

-1.915 (-0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 01

    Feb

  • 26

    Feb

  • 27

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.